









Markets
/
Stocks
/
nasdaq-rdhl
/

Redhill Biopharma Ltd

RDHL

1.080USD

-0.190-14.96%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

3.60MMarket Cap

0.31P/E TTM



Redhill Biopharma Ltd

1.080

-0.190-14.96%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Redhill Biopharma Ltd

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. The company shows very weak stock market performance, in line with its fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Redhill Biopharma Ltd's Score

Industry at a Glance

Industry Ranking

134 / 159

Overall Ranking

527 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Redhill Biopharma Ltd Highlights

StrengthsRisks

RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

Growing

The company is in a growing phase, with the latest annual income totaling USD 8.04M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Overvalued

The company’s latest PE is 0.02, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 87.62K shares, decreasing 31.20% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 4.38, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 1.80M, representing a year-over-year decrease of 90.21%, while its net profit experienced a year-over-year decrease of 106.50%.

Score

Industry at a Glance

Previous score

4.38

Change



Financials

8.93

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

0.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

0.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.98

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

5.00

Key Metrics

Free cash flow

No Data

Redhill Biopharma Ltd's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.44, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 0.02, which is 133.16% below the recent high of 0.04 and 5233.68% above the recent low of -0.99.

Score

Industry at a Glance

Previous score

7.44

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 134/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.77.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 2.12, which is lower than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 1.79 and the support level at 0.72, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.99

Change

0.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.126

Sell

RSI(14)

29.174

Sell

STOCH(KDJ)(9,3,3)

1.951

Oversold

ATR(14)

0.198

High Vlolatility

CCI(14)

-132.667

Sell

Williams %R

99.065

Oversold

TRIX(12,20)

-0.939

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.292

Sell

MA10

1.467

Sell

MA20

1.573

Sell

MA50

1.622

Sell

MA100

1.666

Sell

MA200

2.429

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

UBS Financial Services, Inc.

7.99K

+399250.00%

Desjardins Securities Inc.

3.39K

SBI Securities Co., Ltd.

2.00K

+39980.00%

Morgan Stanley & Co. LLC

1.80K

+16263.64%

Rhumbline Advisers Ltd. Partnership

1.77K

+27.38%

BofA Global Research (US)

303.00

Raymond James Financial Services Advisors, Inc.

204.00

GAMMA Investing LLC

135.00

-93.45%

Group One Trading, L.P.

11.00

-50.00%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 1.48, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 4.82. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.